New data put Lundbeck firmly on GSK's tail in 5HT6 inhibitor Alzheimer's race
This article was originally published in Scrip
Lundbeck's novel selective 5HT6 receptor inhibitor Lu AE58054 may have fallen at the Phase II hurdle in schizophrenia, but the company seems to be reaping the rewards of pursuing its development in the notoriously difficult indication of Alzheimer's disease.
You may also be interested in...
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.
A highly impressive improvement in disease-free survival in ADAURA is set to pitch AstraZeneca’s best-selling product into a new untapped market, early-stage EGFRm NSCLC, reaping a possible $3bn in extra sales.
The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.